Logo image of MDCX

MEDICUS PHARMA LTD (MDCX) Stock Fundamental Analysis

USA - NASDAQ:MDCX - CA58471K2020 - Common Stock

2.39 USD
-0.03 (-1.24%)
Last: 11/7/2025, 8:00:01 PM
2.4399 USD
+0.05 (+2.09%)
After Hours: 11/7/2025, 8:00:01 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MDCX. MDCX was compared to 531 industry peers in the Biotechnology industry. Both the profitability and financial health of MDCX have multiple concerns. MDCX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MDCX has reported negative net income.
MDCX had negative earnings in each of the past 5 years.
MDCX had a negative operating cash flow in each of the past 5 years.
MDCX Yearly Net Income VS EBIT VS OCF VS FCFMDCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -195.00%, MDCX is doing worse than 89.37% of the companies in the same industry.
The Return On Equity of MDCX (-319.45%) is worse than 71.83% of its industry peers.
Industry RankSector Rank
ROA -195%
ROE -319.45%
ROIC N/A
ROA(3y)-358.98%
ROA(5y)-4285.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MDCX Yearly ROA, ROE, ROICMDCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MDCX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDCX Yearly Profit, Operating, Gross MarginsMDCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for MDCX has been increased compared to 1 year ago.
The number of shares outstanding for MDCX has been increased compared to 5 years ago.
There is no outstanding debt for MDCX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MDCX Yearly Shares OutstandingMDCX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MDCX Yearly Total Debt VS Total AssetsMDCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

MDCX has an Altman-Z score of 0.49. This is a bad value and indicates that MDCX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.49, MDCX is in the better half of the industry, outperforming 61.38% of the companies in the same industry.
MDCX has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.07, MDCX is doing worse than 62.13% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 0.49
ROIC/WACCN/A
WACCN/A
MDCX Yearly LT Debt VS Equity VS FCFMDCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

2.3 Liquidity

A Current Ratio of 2.73 indicates that MDCX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.73, MDCX is doing worse than 66.98% of the companies in the same industry.
MDCX has a Quick Ratio of 2.73. This indicates that MDCX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.73, MDCX is not doing good in the industry: 65.11% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.73
MDCX Yearly Current Assets VS Current LiabilitesMDCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.18% over the past year.
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 20.48% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.85%
EPS Next 2Y17.94%
EPS Next 3Y16.61%
EPS Next 5Y20.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDCX Yearly Revenue VS EstimatesMDCX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
MDCX Yearly EPS VS EstimatesMDCX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MDCX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDCX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDCX Price Earnings VS Forward Price EarningsMDCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDCX Per share dataMDCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as MDCX's earnings are expected to grow with 16.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.94%
EPS Next 3Y16.61%

More info and screens

0

5. Dividend

5.1 Amount

MDCX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDICUS PHARMA LTD

NASDAQ:MDCX (11/7/2025, 8:00:01 PM)

After market: 2.4399 +0.05 (+2.09%)

2.39

-0.03 (-1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-21 2025-11-21
Inst Owners10.3%
Inst Owner ChangeN/A
Ins Owners12.09%
Ins Owner Change11.39%
Market Cap48.33M
Revenue(TTM)N/A
Net Income(TTM)-11.16M
Analysts82.22
Price Target22.78 (853.14%)
Short Float %1.96%
Short Ratio0.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-68.45%
Min EPS beat(2)-76.47%
Max EPS beat(2)-60.43%
EPS beat(4)1
Avg EPS beat(4)-54%
Min EPS beat(4)-118.27%
Max EPS beat(4)39.15%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.56%
PT rev (3m)13.56%
EPS NQ rev (1m)3.33%
EPS NQ rev (3m)-22.53%
EPS NY rev (1m)-14.29%
EPS NY rev (3m)-21.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 13.84
P/tB 13.84
EV/EBITDA N/A
EPS(TTM)-1.87
EYN/A
EPS(NY)-1.22
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -195%
ROE -319.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-358.98%
ROA(5y)-4285.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.73
Altman-Z 0.49
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.6%
EPS Next Y30.85%
EPS Next 2Y17.94%
EPS Next 3Y16.61%
EPS Next 5Y20.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-320.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-146.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-146.43%
OCF growth 3YN/A
OCF growth 5YN/A

MEDICUS PHARMA LTD / MDCX FAQ

Can you provide the ChartMill fundamental rating for MEDICUS PHARMA LTD?

ChartMill assigns a fundamental rating of 1 / 10 to MDCX.


Can you provide the valuation status for MEDICUS PHARMA LTD?

ChartMill assigns a valuation rating of 0 / 10 to MEDICUS PHARMA LTD (MDCX). This can be considered as Overvalued.


What is the profitability of MDCX stock?

MEDICUS PHARMA LTD (MDCX) has a profitability rating of 0 / 10.